Skip to Main Content

Hello, everyone, and how are you today? The middle of the week has arrived, and this is cause for celebration. You made it this far, so why not? After all, consider the alternatives. So please join us as we down another delicious cup of stimulation — Cinnamon Dolce is a favorite this week. Remember, no prescription is required. Meanwhile, here is the usual menu of interesting items to help you moving. Hope you have a smashing day …

The Food and Drug Administration approved Roche’s new Tecentriq immunotherapy as a second-line lung cancer treatment, which is likely to add further pressure on Bristol-Myers Squibb in the fast-growing market, Reuters notes. The medication is approved for non-small cell lung cancer patients who were previously treated with chemotherapy, regardless of whether their tumors express a protein called PD-L1.


Despite bashing the biopharma industry several times over the past year, Hillary Clinton garnered support from nearly two-thirds of 105 biotech executives surveyed in a poll by Endpoints. Only 10 percent preferred Donald Trump and the rest were indifferent. Meanwhile, health care stocks have been sliding this year and are on pace for the first yearly decline since the bull market began in 2009, Bloomberg News notes.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!